Is the monitoring of anti-Xa activity necessary in pregnant women undergoing thromboprophylaxis?

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 114, Issue 1, 2004, Pages 12-14

  O'Connell, Michael P ^a,b   O'Leary, Michael ^a   MacKeogh, Luke ^a   Murphy, Karen ^a   Keane, Declan P ^a  

^a NATIONAL MATERNITY HOSPITAL   (Ireland)

^b Pathology Research Laboratory   (Ireland)

Author keywords

Anti Xa activity; Pregnant women; Thromboprophylactic

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTIBODY; ENOXPARIN; PROTHROMBIN ANTIBODY; TINZAPARIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PROTEIN FUNCTION; THROMBOSIS;

EID: 1942476003     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2003.09.010     Document Type: Article

References (8)

1. Dulitzi M., Pauzner R., Langevitz P., Pras M., Many A., Schiff E. Low molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol. 87:1996;380-383.
2. Leizorovicz A., Haugh M.C., Chapuis F.R.et al. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ. 305:1992;913-920.
3. Warkentin T.E., Levine M.N., Hirsh J.et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl. J. Med. 332:1995;1330-1335.
4. Monreal M., Lafoz E., Olive A., del Rio L., Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 71:1994;7-11.
5. Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in gynaecology and pregnancy: recommendations for prophylaxis. London: The College; 1995.
6. Nelson-Piercy C., Letsky E.A., De Swiet M. Low molecular weight heparin for obstetric prophylaxis:experience in sixty nine pregnancies in sixty one women at high risk. Am J. Obstet. Gynecol. 176:1997;1062-1068.
7. Boneau B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost. 72:1994;330-334.
8. Brennand J.E., Walker I.D., Greer I.A. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol. 101:1999;53-55.